Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

1. EWTX reported positive results from Phase 2 CIRRUS-HCM trial for EDG-7500. 2. EDG-7500 showed significant reductions in left ventricular outflow tract gradient. 3. 78% of obstructive HCM participants improved by ≥ 1 NYHA Class. 4. Treatment resulted in a 62% reduction in NT-proBNP biomarker levels. 5. Initial data from Part D expected in late 2025, Ph3 starts in H1 2026.